Document is current
Any future updates will be listed below
-
Authors
Arnold, Matthias https://orcid.org/0000-0002-4666-0923
Buyukozkan, Mustafa https://orcid.org/0000-0001-5027-5078
Doraiswamy, P. Murali
Nho, Kwangsik
Wu, Tong https://orcid.org/0000-0002-2296-3380
Gudnason, Vilmundur https://orcid.org/0000-0001-5696-0084
Launer, Lenore J. https://orcid.org/0000-0002-3238-7612
Wang-Sattler, Rui https://orcid.org/0000-0002-8794-8229
Adamski, Jerzy
,
,
De Jager, Philip L. https://orcid.org/0000-0002-8057-2505
Ertekin-Taner, Nilüfer https://orcid.org/0000-0003-4436-8889
Bennett, David A.
Saykin, Andrew J. https://orcid.org/0000-0002-1376-8532
Peters, Annette
Suhre, Karsten https://orcid.org/0000-0001-9638-3912
Kaddurah-Daouk, Rima https://orcid.org/0000-0003-1858-5732
Kastenmüller, Gabi https://orcid.org/0000-0002-2368-7322
Krumsiek, Jan https://orcid.org/0000-0003-4734-3791
- License Information
-
More Information
Article History
Received: 19 November 2023
Accepted: 4 February 2025
First Online: 24 February 2025
Competing interests
: A.J.S. is a member of the Scientific Advisory Board of Bayer Oncology and of the Dementia Advisory Board of Siemens Medical Solutions USA, Inc.; A.J.S received in-kind support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (PET tracer precursor); A.J.S. received Editorial Office Support as Editor-in-Chief from Springer-Nature Publishing (Brain Imaging and Behavior). P.M.D. has received research grants (through Duke University) from Lilly, Avanir, Bausch, Alzheimer’s Drug Discovery Foundation; P.M.D. has received advisory fees from Verily, Otsuka, Genomind, Cogniciti, Clearview, VitaKey, Neuronix, Neuroglee, and Transposon Therapeutics; P.M.D. owns shares or options in UMethod, Evidation Health, Transposon, Marvel Biome, and Advera Health; P.M.D. serves on the board of Apollo and is a co-inventor (through Duke University) on patents relating to dementia biomarkers, metabolomics, and therapies. R.K.D holds equity in Metabolon Inc. M.A., R.K.D., and G.K. are co-inventors (through Duke University/Helmholtz Zentrum München) on patents on applications of metabolomics in diseases of the central nervous system; M.A., R.K.D., G.K., and J.K. hold equity in Chymia LLC and IP in PsyProtix/atai Life Sciences N.V. that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in treatment-resistant depression. JK is a confounder of iollo, advisor to Everfur, and advisor/part-time employee at ExactRx. The remaining authors declare no competing interests.
